The vaccine developed indigenously by India has shown an interim efficacy of 81% in preventing COVID-19 during phase 3 trials

Zimbabwe has become the first country in Africa to approve the use of India’s indigenously developed Covaxin.

“Zimbabwe has authorized use of COVAXIN, India's indigenous COVID-19 vaccine, becoming the first country in Africa to do so. Trying to get it to Zimbabwe at an early date,” said the Embassy of India in Zimbabwe in a tweet.


The development comes as the world is showing trust in made in India vaccines. Recently, Ghana became the first country to receive India manufactured Covid-19 vaccines.

600,000 doses of vaccine produced by the Serum Institute of India were delivered to Ghana last week.

While on one side other countries are showing confidence in India's vaccine, on the other hand, India has also come forward and given the Corona vaccine as a gift to many countries.

It is also important to note that the results of phase 3 clinical trial of COVAXIN, which the Indian Council of Medical Research (ICMR) has developed in partnership with Bharat Biotech, has shown an interim vaccine efficacy of 81% in preventing COVID-19 as on March 3.

The phase 3 clinical trial was jointly initiated by ICMR and Bharat Biotech International Limited in mid-November 2020.

The trial has been conducted on a total of 25,800 individuals across 21 sites, ICMR announced on Wednesday.

The interim efficacy trend of 81%, analyzed as per the protocol approved by the Drugs Controller General of India (DCGI), puts it at par with other global front-runner vaccines.